1R3 Stock Overview
A research and development company, develops diagnostic products for detecting breast cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Izotropic Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.011 |
| Beta | 1.77 |
| 1 Month Change | 845.83% |
| 3 Month Change | 137.45% |
| 1 Year Change | 6.57% |
| 3 Year Change | -81.98% |
| 5 Year Change | -3.81% |
| Change since IPO | -44.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1R3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 203.5% | 0.9% | 1.3% |
| 1Y | 6.6% | -9.7% | 9.0% |
Return vs Industry: 1R3 exceeded the German Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: 1R3 underperformed the German Market which returned 9% over the past year.
Price Volatility
| 1R3 volatility | |
|---|---|
| 1R3 Average Weekly Movement | 62.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1R3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1R3's weekly volatility has increased from 39% to 63% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Bob Thast | izocorp.com |
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada.
Izotropic Corporation Fundamentals Summary
| 1R3 fundamental statistics | |
|---|---|
| Market cap | €6.72m |
| Earnings (TTM) | -€1.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs 1R3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1R3 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.90m |
| Earnings | -CA$1.90m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -44.3% |
How did 1R3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 18:31 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Izotropic Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|